Related Experiment Video
Updated: Jun 14, 2025
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Efficacy of Short-Course High-Dose Oral Prednisolone in Rapid Platelet Recovery for Pediatric Acute Immune
Akshat Jhingan1, Neha Goel1, Amitabh Singh1
1Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India.
Insights
Short-course high-dose prednisolone (PDN) effectively treats acute immune thrombocytopenic purpura (ITP) in children, accelerating platelet recovery. This approach offers a well-tolerated first-line therapy with minimal side effects.
Area of Science:
- Pediatric Hematology
- Immunology
- Pharmacology
Background:
- Management of acute immune thrombocytopenic purpura (ITP) in children is debated.
- Corticosteroids like prednisolone (PDN) are common first-line treatments for ITP.
- This study focuses on short-course high-dose PDN for newly diagnosed acute ITP in children.
Purpose of the Study:
- To evaluate the effectiveness of short-course high-dose PDN in treating pediatric acute ITP.
- To assess the clinical and hematological profiles of children with ITP.
- To determine the mean time to platelet recovery after PDN treatment.
Main Methods:
- Prospective cohort study design.
- Inclusion of 61 children aged 1-12 years with newly diagnosed acute ITP.
- Monitoring of platelet counts at 48h, 72h, day 7, 1 month, and 3 months.
Main Results:
- 83.6% of patients achieved platelet counts >50,000/mm³ by day 7.
- 91.8% maintained platelet recovery at 1 month.
- Children aged 6-12 years showed a higher risk (24.5%) of persistent ITP.
Conclusions:
- Short-course high-dose PDN is an effective first-line therapy for acute ITP in children.
- PDN promotes rapid platelet recovery and may reduce hospitalization.
- The treatment is generally well-tolerated with mild side effects.
Background:
Standard management of acute immune thrombocytopenic purpura (ITP) remains debated, with some advocating observation for mild cases, while others recommend pharmacological intervention to accelerate platelet recovery in children with severe thrombocytopenia (TCP) (platelet count < 20,000/mm3) or significant mucosal bleeds. Corticosteroids, particularly prednisolone (PDN), are a widely used first-line treatment due to their rapid immunosuppressive effect. This prospective cohort study evaluated the effectiveness of short-course high-dose PDN (4 mg/kg/day for 7 days) in treating children aged 1 - 12 years with newly diagnosed acute ITP. The study aimed to assess the clinical and hematological profile of these children and the mean time to platelet recovery.
Methods:
A total of 61 patients were enrolled, and their response to treatment was monitored at various intervals, including 48 h, 72 h, day 7, 1 month, and 3 months.
Results:
Results revealed a rapid platelet recovery in patients receiving high-dose PDN, with 83.6% of patients achieving platelet counts greater than 50,000/mm3 by day 7. Additionally, 91.8% maintained platelet recovery at 1 month. The study also found that the age group 6 - 12 years had a higher risk of persistent ITP (24.5%), highlighting the importance of close monitoring in this demographic. While the treatment was generally well tolerated, some mild side effects like hypertension and glycosuria were observed.
Conclusion:
The study suggests that short-course high-dose PDN can be an effective first-line therapy for acute ITP. It promotes faster platelet recovery and reduces hospitalization time with minimal adverse effects.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...